Company Analysis

Nuvectis Pharma, Inc. (NVCT)

Nasdaq: NVCT · Pharmaceutical Preparations · Fort Lee, NJ · filing with the SEC since 2021
Grade6.1
◀ Past 5.8● Present 5.8▶ Future 6.7
7 est.

Filings

136 filings since 2017 beside 139 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 35 days after the quarter ended. The proxy statement was last filed Apr 27, 2026.

Filings a yearinsider forms included
227968343735
202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 1 time in the last 36 months, the newest Sep 25, 2025.SEC letters: 2 in the last 36 months, the newest Feb 18, 2026.
Insider forms 139

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 4, 2026 10-Q Quarterly report Sep 30, 2026
Nov 4, 2026 8-K items 2.02, 9.01 Results released · Current report
Aug 28, 2026 EFFECT Registration effective
Aug 21, 2026 S-3 Shelf registration
Aug 21, 2026 8-K items 8.01, 9.01 Other event · Current report Jul 20, 2026
Aug 6, 2026 SCHEDULE 13G Large holder notice
Aug 4, 2026 10-Q Quarterly report Jun 30, 2026
Aug 4, 2026 8-K items 2.02, 9.01 Results released · Current report
Jun 30, 2026 8-K items 1.01, 8.01, 9.01 Major agreement signed; Other event · Current report Jun 29, 2026
Jun 30, 2026 424B5 Shelf offering
Jun 29, 2026 424B5 Shelf offering
Jun 29, 2026 8-K item 8.01 Other event · Current report
Jun 23, 2026 8-K items 1.01, 8.01, 9.01 Major agreement signed; Other event · Current report Jun 22, 2026
Jun 12, 2026 8-K item 5.07 Shareholder vote · Current report Jun 11, 2026
May 5, 2026 10-Q Quarterly report Mar 31, 2026
May 5, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 27, 2026 DEFA14A Extra proxy material
Apr 27, 2026 DEF 14A Proxy statement Jun 11, 2026
Feb 20, 2026 EFFECT Registration effective
Feb 18, 2026 CORRESP Reply to the SEC
Feb 18, 2026 UPLOAD SEC comment letter
Feb 13, 2026 S-3 Shelf registration
Feb 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Feb 11, 2026 10-K Annual report Dec 31, 2025
Nov 4, 2025 8-K items 2.02, 9.01 Results released · Current report
Nov 4, 2025 10-Q Quarterly report Sep 30, 2025
Sep 25, 2025 8-K items 5.02, 9.01 Officer or director change · Current report Sep 22, 2025
Aug 5, 2025 10-Q Quarterly report Jun 30, 2025
Aug 5, 2025 8-K items 2.02, 9.01 Results released · Current report
Jun 13, 2025 8-K item 5.07 Shareholder vote · Current report Jun 12, 2025
May 9, 2025 8-K items 8.01, 9.01 Other event · Current report
May 9, 2025 424B5 Shelf offering
May 6, 2025 10-Q Quarterly report Mar 31, 2025
May 6, 2025 8-K items 2.02, 9.01 Results released · Current report
Apr 28, 2025 DEFA14A Extra proxy material
Apr 28, 2025 DEF 14A Proxy statement Jun 12, 2025
Feb 25, 2025 10-K Annual report Dec 31, 2024
Feb 25, 2025 8-K items 2.02, 9.01 Results released · Current report
Feb 6, 2025 8-K items 1.01, 8.01, 9.01 Major agreement signed; Other event · Current report Feb 5, 2025
Feb 6, 2025 424B5 Shelf offering
40 of 136 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton NVCT · research, not advice